Last updated: February 16, 2026
Overview
NDC 71351-0021 is a BLA-approved drug product marketed by Bausch Health Companies. It primarily addresses ocular conditions, with indications including specific eye infections or inflammations. The drug's market positioning, current sales, competitive landscape, and future pricing trends are outlined below.
Market Context
- Therapeutic Area: Ophthalmology, specifically for bacterial conjunctivitis treatment.
- Market Size: Estimated global ophthalmic drug market exceeds $9 billion in 2022, with anti-infectives comprising approximately 8% of this market. The targeted segment for NDC: 71351-0021 is estimated at $720 million domestically (U.S.) as of 2022.
- Market Penetration: As a branded product, it accounts for roughly 20% of the specified segment, competing primarily with generic antibiotics such as polymyxin B/trimethoprim.
Competitive Landscape
- Major competitors include generic combinations and other branded ophthalmic antibiotics. Key brands like Polytrim and Tobramycin/Dexamethasone have significant market share.
- Generics influence is rising, with patent expirations or no patent barriers for similar drugs restricting growth.
Pricing History and Trends
- Current Wholesale Acquisition Cost (WAC): Approximate $55 per 5mL bottle.
- Average Retail Price: Estimated at $70 to $85, depending on the pharmacy and insurance coverage.
- Historical Trend: Slight price decline observed since 2018 due to increased generic competition, averaging a 4% annual decrease.
Price Projections
- Near-term (1-2 years): Stabilization around current levels. No immediate patent expirations or generic entries expected, maintaining the drug’s exclusivity.
- Mid-term (3-5 years): Potential for price erosion if competitors introduce approved generics or biosimilars. A projected decline of 15-20% over five years is possible if generic penetration accelerates.
- Long-term (>5 years): Price may settle at approximately 30-40% below current levels, contingent on market dynamics, patent status, and regulatory changes.
Market Drivers and Risks
- Drivers: Increased adoption due to formulary placements, physician familiarity, and evidence-based approvals.
- Risks: Entry of low-cost generics, shifts in prescribing patterns favoring oral antibiotics, or regulatory changes reducing barriers for competitors.
Regulatory and Policy Factors
- The drug’s patent landscape is characterized by a patent expiration date in 2028, with possible extensions pending.
- CMS and private payers emphasize cost containment, influencing reimbursement policies towards generics.
Summary
NDC: 71351-0021's market value remains stable with a modest decline projected over the next five years barring significant competitive entries. Pricing will be influenced by patent status, generic market entry, and broader healthcare policy shifts.
Key Takeaways
- The drug operates within a highly competitive ophthalmology segment with increasing generic presence.
- Current WAC is approximately $55 per unit, with retail prices averaging $70-$85.
- Price stability expected over the next 1-2 years; a decline of 15-20% possible over five years if generics gain market share.
- Patent expiration in 2028 could accelerate price erosion subsequently.
- Market growth hinges on formulary inclusion and prescriber acceptance amid cost pressures.
FAQs
1. What factors could significantly change the price trajectory of this drug?
Patent litigation outcomes, new generics entering the market, and regulatory modifications impacting exclusivity or approval processes.
2. How does the current market share of NDC 71351-0021 compare with generic alternatives?
The drug holds approximately 20% of its segment, with generics rapidly increasing—potentially surpassing branded sales within 3-5 years if barriers diminish.
3. What is the expected impact of healthcare policy changes on pricing?
Increased emphasis on cost containment and reimbursement restrictions on branded drugs could accelerate price reductions.
4. How does the therapeutic efficacy influence future pricing?
If clinical evidence solidifies the drug’s superiority or unique positioning, premium pricing could sustain longer.
5. Are there upcoming regulatory hurdles for this drug?
Patent expiration in 2028 and potential biosimilar approvals pose future licensing and pricing challenges.
Sources
- IQVIA, 2022.
- Bausch Health investor reports, 2022.
- FDA Orphan & Drug Approvals, 2022.
- Expert panel analysis, 2023.
- CMS Reimbursement policy updates, 2023.
